resistance therapy caused intragenic deletion brca2 
cells loss brca2 function defective homologous recombination hr highly sensitive inhibitors poly adp ribose polymerase parp provides basis new therapeutic approach show resistance parp inhibition can acquired deletion mutation brca2 derived parp inhibitor resistant pir clones human capan1 pancreatic cancer cell line carries protein truncating c6174delt frameshift mutation pir clones form dna damage induced rad51 nuclear foci able limit genotoxin induced genomic instability hallmarks competent hr pathway new brca2 isoforms expressed resistant lines result intragenic deletion c6174delt mutation restoration open reading frame orf reconstitution brca2 deficient cells revertant brca2 alleles rescued parp inhibitor sensitivity hr deficiency deletions brca2 associated small tracts homology possibly arose error-prone repair caused brca2 deficiency similar orf-restoring mutations present carboplatin resistant ovarian tumours c6174delt mutation carriers observations implications understanding drug resistance brca mutation carriers well defining functionally important domains within brca2 
